Sharekhan's research report on Aarti Industries
Q3FY2021 results were strong with a 16%/19.4% beat in operating profit/adjusted PAT at Rs. 285 crore/ Rs. 155 crore led by strong OPM of 24% (401 bps above our estimate) as gross margins surged to 54% (up 303 bps y-o-y). Specialty chemicals’ EBIT margin rose sharply by 356 bps q-o-q to 20.5% (close to pre-COVID-19 level) led by higher share of VAP at 76% versus 72% in Q2FY21 and normalisation of discretionary demand; pharmaceutical EBIT margins were also resilient at 23.8% (up 338 bps y-o-y). Recent recovery in specialty chemicals and ongoing capex of Rs. 2,500 crore over FY2021EFY2022E to drive EBITDA/PAT CAGR of 21%/24% over FY2020-FY2023E. Management is also looking to demerge pharma business and list it separately that could help unlock value.
Outlook
We believe Aarti Industries would be a key beneficiary of China plus one factor and import substitution in domestic markets for specialty chemicals. Hence, we maintain a Buy rating on the stock with a revised PT of Rs. 1,355.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!